Comparative Pharmacology
Head-to-head clinical analysis: DELAXIN versus SKELAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELAXIN versus SKELAXIN.
DELAXIN vs SKELAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DELAXIN (cyclobenzaprine) is a centrally acting muscle relaxant that is thought to relieve muscle spasms by inhibiting the descending serotonergic pathways in the spinal cord, specifically at the level of the brainstem. It acts as a serotonin 5-HT2 receptor antagonist, reducing excessive motor neuron activity.
Skelaxin (metaxalone) is a centrally acting skeletal muscle relaxant. Its exact mechanism of action is not fully understood, but it is believed to act primarily by depressing the central nervous system (CNS) through inhibition of polysynaptic reflexes at the spinal and supraspinal levels, leading to muscle relaxation without directly affecting the neuromuscular junction or muscle fibers.
10 mg orally once daily, preferably at bedtime.
800 mg orally three to four times daily.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment; up to 30 hours in severe renal failure).
1-2 hours (terminal elimination half-life); clinical context: short duration of action, requires multiple daily dosing
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites.
Primarily renal (approximately 99% as unchanged drug); <1% fecal
Category C
Category C
Skeletal muscle relaxant
Skeletal muscle relaxant